Immune microenvironment of gliomas

Laboratory Investigation

Volumn 97, Issue 5, 2017, Pages 498-518

  Gieryng, Anna ^a   Pszczolkowska, Dominika ^a   Walentynowicz, Kacper A ^a   Rajan, Wenson D ^a   Kaminska, Bozena ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL INTERACTION; CELL REPROGRAMMING TECHNIQUE; GLIOMA; HELPER CELL; HUMAN; IMMUNE EVASION; IMMUNOCOMPETENT CELL; LEUKOCYTE; MACROPHAGE; MICROGLIA; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NERVE CELL PLASTICITY; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; IMMUNOLOGY; MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; MACROPHAGES; MICE; MICROGLIA; TUMOR MICROENVIRONMENT;

EID: 85019644316     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2017.19     Document Type: Review

References (248)

1. Ilkanizadeh S, Lau J, Huang M, et al. Glial progenitors as targets for transformation in glioma. Adv Cancer Res 2014; 121: 1-65.
2. Weller M, Stupp R, Hegi ME, et al. Personalized care in neurooncology coming of age: Why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012; 14: iv100-iv108.
3. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14: e370-e379.
4. Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164: 550-563.
5. Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med. 2009; 7: 77.
6. Tabatabai G, Stupp R, Van Den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 2010; 120: 585-592.
7. Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 2015; 3: 95.
8. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
9. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66: 3294-3302.
10. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumorderived TGF-β. Clin Cancer Res 2011; 17: 4296-4308.
11. Alexiou GA, Vartholomatos G, Karamoutsios A, et al. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma. Acta Neurol Belg 2013; 113: 7-11.
12. Wainwright DA, Dey M, Chang A, et al. Targeting tregs in malignant brain cancer: overcoming IDO. Front Immunol 2013; 4: 116.
13. Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol 2015; 5: 153.
14. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003; 63: 6613-6625.
15. Shirahata M, Iwao-Koizumi K, Saito S, et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007; 13: 7341-7356.
16. Vauleon E, Tony A, Hamlat A, et al. Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics 2012; 5: 41.
17. Guillemin GJ, Brew BJ. Microglia macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004; 75: 388-397.
18. Kaminska B. Microglia in gliomas: friend or foe?. In: Sedo A, Mentlein R (eds). Glioma Cell Biology. Vienna: Springer, 2014, pp 241-270.
19. Esiri MM, Morris CS. Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease. 2. Non-neoplastic diseases. J Neurol Sci 1991; 101: 59-72.
20. Wierzba-Bobrowicz T, Kuchna I, Matyja E. Reaction of microglial cells in human astrocytomas (preliminary report). Folia Neuropathol 1994; 32: 251-252.
21. Geranmayeh F, Scheithauer BW, Spitzer C, et al. Microglia in gemistocytic astrocytomas. Neurosurgery 2007; 60: 159-166.
22. Mieczkowski J, Kocyk M, Nauman P, et al. Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget 2015; 6: 33077-33090.
23. Sedgwick JD, Schwender S, Imrich H, et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA 1991; 88: 7438-7442.
24. Sedgwick JD. Resident macrophages (ramified microglia) of the adult brown Norway rat central nervous system are constitutively major histocompatibility complex class II positive. J Exp Med 1993; 177: 1145-1152.
25. Badie B, Schartner JM. Flow cytometric characterization of tumorassociated macrophages in experimental gliomas. Neurosurgery 2000; 46: 957-962.
26. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8: 261-279.
27. Badie B, Schartner J. Role of microglia in glioma biology. Microsc Res Tech 2001; 54: 106-113.
28. Yi L, Xiao H, Xu M, et al. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 2011; 232: 75-82.
29. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14-20.
30. Murray PJ, Wynn T. A. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89: 557-563.
31. Ostuni R, Kratochvill F, Murray PJ, et al. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 2015; 36: 229-239.
32. Kratochvill F, Neale G, Haverkamp JM, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep 2015; 12: 1902-1914.
33. Ellert-miklaszewska A, Ciechomska I, Kaminska B. Glioma signaling. Adv Exp Med Biol 2013; 986: 209-220.
34. Durafourt BA, Moore CS, Zammit DA, et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012; 60: 717-727.
35. Walker DG, Lue L. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 2015; 7: 56.
36. Kaminska B, Mota M, Pizzi M. Signal transduction and epigenetic mechanisms in the control of microglia activation during neuroinflammation. Biochim Biophys Acta-Mol Basis Dis 2016; 1862: 339-351.
37. Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
38. Huettner C, Czub S, Kerkau S, et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 1997; 17: 3217-3224.
39. Wagner S, Czub S, Greif M, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 1999; 82: 12-16.
40. Szulzewsky F, Pelz A, Feng X, et al. Glioma-Associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS ONE 2015; 10: e0116644.
41. Szulzewsky F, Arora S, de Witte L, et al. Human glioblastomaassociated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. Glia 2016; 64: 1416-1436.
42. Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI insight 2016; 1: 1-32.
43. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347.
44. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol 2015; 74: 390-400.
45. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment : expect the unexpected. J Clin Investig 2015; 125: 3356-3364.
46. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13: 591-599.
47. Dubinski D, Wölfer J, Hasselblatt M, et al. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol 2015; 18: 807-818.
48. Wainwright DA, Sengupta S, Han Y, et al. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011; 13: 1308-1323.
49. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14: 5166-5172.
50. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003; 63: 7462-7467.
51. Jacobs JFM, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010; 225: 195-199.
52. Kmiecik J, Poli A, Brons NHC, et al. Elevated CD3+ and CD8+ tumorinfiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 2013; 264: 71-83.
53. Borrego F, Kabat J, Kim D-KK, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002; 38: 637-660.
54. Ryan JC, Naper C, Hayashi S, et al. Physiologic functions of activating natural killer (NK) complex-encoded receptors on NK cells. Immunol Rev 2001; 181: 126-137.
55. Wiendl H, Mitsdoerffer M, Hofmeister V, et al A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168: 4772-4780.
56. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63: 8996-9006.
57. Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129: 2416-2425.
58. Fadul CE, Fisher JL, Gui J, et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011; 13: 393-400.
59. Poli A, Wang J, Domingues O, et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 2013; 4: 1527-1546.
60. Ogbomo H, Cinatl J, Mody CH, et al. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol Med 2017; 17: 433-441.
61. Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 2011; 104: 545-553.
62. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006; 12: 5288-5297.
63. Stylli SS, Luwor RB, Ware TMB, et al. Mouse models of glioma. J Clin Neurosci 2015; 22: 619-626.
64. Auer RN, Del Maestro RF, Anderson R A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 1981; 8: 325-331.
65. Sibenaller Za, Etame AB, Ali MM, et al. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg Focus 2005; 19: E1.
66. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 2008; 1: 78-82.
67. Shankavaram UT, Bredel M, Burgan WE, et al. Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. J Cell Mol Med 2012; 16: 545-554.
68. Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 2009; 19: 132-143.
69. Holland EC, Celestino J, Dai C, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25: 55-57.
70. McKinney AJ, Holmen SL. Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin J Cancer 2011; 30: 153-162.
71. Sukhdeo K, Hambardzumyan D, Rich JN. Glioma development: where did it all go wrong?. Cell 2011; 146: 187-188.
72. Hambardzumyan D, Amankulor NM, Helmy KY, et al. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2009; 2: 89-95.
73. Badie B, Bartley B, Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol 2002; 133: 39-45.
74. Gabrusiewicz K, Hossain MB, Cortes-Santiago N, et al. Macrophage ablation reduces M2-Like populations and jeopardizes tumor growth in a MAFIA-based glioma model. Neoplasia 2015; 17: 374-384.
75. Ellert-Miklaszewska A, Dabrowski M, Lipko M, et al. Molecular definition of the pro-Tumorigenic phenotype of glioma-Activated microglia. Glia 2013; 61: 1178-1190.
76. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, et al. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS ONE 2011; 6: e23902.
77. Sielska M, Przanowski P, Wylot B, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol 2013; 230: 310-321.
78. Levy A, Blacher E, Vaknine H, et al. CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-Associated microglia/macrophages. Neuro Oncol 2012; 14: 1037-1049.
79. Raychaudhuri B, Rayman P, Huang P, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol 2015; 122: 293-301.
80. Kennedy BC, Maier LM, D'Amico R, et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol 2009; 10: 11.
81. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-Associated macrophages. Laboratory investigation. J Neurosurg 2009; 110: 572-582.
82. Ahn B, Kohanbash G, Ohkuri T, et al. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology 2015; 4: e1047581.
83. Maes W, Verschuere T, Van Hoylandt A, et al. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol 2013; 2013: 952469.
84. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron 2013; 77: 10-18.
85. London A, Cohen M, Schwartz M. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 2013; 7: 34.
86. Zhan Y, Paolicelli RC, Sforazzini F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2014; 17: 400-406.
87. Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia 2011; 59: 177-187.
88. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2014; 330: 841-845.
89. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2015; 19: 20-27.
90. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol 2014; 128: 347-362.
91. Campanella M, Sciorati C, Tarozzo G, et al. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002; 33: 586-592.
92. O'Koren EG, Mathew R, Saban DR. Fate mapping reveals that microglia and recruited monocyte-derived macrophages are definitively distinguishable by phenotype in the retina. Sci Rep 2016; 6: 20636.
93. Lavin Y, Winter D, Blecher-Gonen R, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014; 159: 1312-1326.
94. Gosselin D, Link VM, Romanoski CE, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014; 159: 1327-1340.
95. Hickman SE, Kingery ND, Ohsumi TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 2013; 1: 1896-1905.
96. Satoh J Ichi, Kino Y, Asahina N, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology 2016; 36: 39-49.
97. Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci 2014; 17: 131-143.
98. Sieber MW, Jaenisch N, Brehm M, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS ONE 2013; 8: e52982.
99. Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201: 647-657.
100. Müller A, Brandenburg S, Turkowski K, et al. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int J Cancer 2015; 137: 278-288.
101. Lahmar Q, Keirsse J, Laoui D, et al. Tissue-resident versus monocytederived macrophages in the tumor microenvironment. Biochim Biophys Acta-Rev Cancer 2016; 1865: 23-34.
102. Badie B, Schartner J, Klaver J, et al. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery 1999; 44: 1077-1083.
103. Kunkel P, Müller S, Schirmacher P, et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro Oncol 2001; 3: 82-88.
104. Sonnenberg E, Meyer D, Weidner KM, et al. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993; 123: 223-235.
105. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57: 5391-5398.
106. Esencay M, Newcomb EW, Zagzag D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol 2010; 99: 33-40.
107. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 2002; 94: 3210-3218.
108. Tu H, Zhou Z, Liang Q, et al. CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie 2009; 32: 331-336.
109. Laterra J, Rosen E, Nam M, et al. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem Biophys Res Commun 1997; 235: 743-747.
110. Moriyama T, Kataoka H, Hamasuna R, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 1998; 249: 73-77.
111. Eckerich C, Zapf S, Fillbrandt R, et al. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 2007; 121: 276-283.
112. Sheng-hua C, Yan-bin M, Zhi-An Z, et al. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg Neurol 2007; 68: 610-613.
113. Prat E, Baron P, Meda L, et al. The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with β-Amyloid protein. Neurosci Lett 2000; 283: 177-180.
114. Platten M, Kretz A, Naumann U, et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 2003; 54: 388-392.
115. Leung SY, Wong MP, Chung LP, et al. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997; 93: 518-527.
116. Desbaillets I, Tada M, De Tribolet N, et al. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 1994; 58: 240-247.
117. Kuratsu J, Yoshizato K, Yoshimura T, et al. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 1993; 85: 1836-1839.
118. Hinojosa AE, Garcia-Bueno B, Leza JC, et al. CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011; 8: 77.
119. Okada M, Saio M, Kito Y, et al. Tumor-Associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol 2009; 34: 1621-1627.
120. Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
121. Menten P, Wuyts A, Van Damme J. Monocyte chemotactic protein-3. Eur Cytokine Netw 2001; 12: 554-560.
122. Serbina NV, Jia T, Hohl TM, et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008; 26: 421-452.
123. Kirk EA, Sagawa ZK, McDonald TO, et al. Monocyte chemoattractant protein-1 deficiency fails to restrain macrophage infiltration into adipose tissue. Diabetes 2008; 57: 1254-1261.
124. Liang Y, Bollen AW, Gupta N. CC chemokine receptor-2A is frequently overexpressed in glioblastoma. J Neurooncol 2008; 86: 153-163.
125. Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature 1996; 382: 80-83.
126. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Natur 1996; 381: 785-789.
127. Lapchak PA, Jiao S, Collins F, et al. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 1997; 747: 92-102.
128. Unsicker K. GDNF: a cytokine at the interface of TGF-betas and neurotrophins. Cell Tissue Res 1996; 286: 175-178.
129. Hunot S, Bernard V, Faucheux B, et al. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease. J Neural Transm 1996; 103: 1043-1052.
130. Pochon NAM, Menoud A, Tseng JL, et al. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 1997; 9: 463-471.
131. Moretto G, Walker DG, Lanteri P, et al. Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes in vitro. Cell Tissue Res 1996; 286: 257-262.
132. Schaar DG, Sieber Ba, Dreyfus CF, et al. Regional and cell-specific expression of GDNF in rat brain. Expl Neurol 1993; 124: 368-371.
133. Lin L, Doherty D, Lile J, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
134. Verity a N, Wyatt TL, Hajos B, et al. Regulation of glial cell line-derived neurotrophic factor release from rat C6 glioblastoma cells. J Neurochem 1998; 70: 531-539.
135. Verity AN, Wyatt TL, Lee W, et al. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J Neurosci Res 1999; 55: 187-197.
136. Batchelor PE, Liberatore GT, Wong JYF, et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell linederived neurotrophic factor. J Neurosci 1999; 19: 1708-1716.
137. Wiesenhofer B, Stockhammer G, Kostron H, et al. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-Alpha 1) are strongly expressed in human gliomas. Acta Neuropathol 2000; 99: 131-137.
138. Cornejo M, Nambi D, Walheim C, et al. Effect of NRG1, GDNF, EGF and NGF in the migration of a Schwann cell precursor line. Neurochem Res 2010; 35: 1643-1651.
139. Dudanova I, Gatto G, Klein R. GDNF acts as a chemoattractant to support ephrina-induced repulsion of limb motor axons. Curr Biol 2010; 20: 2150-2156.
140. Ku MC, Wolf SA, Respondek D, et al. GDNF mediates glioblastomainduced microglia attraction but not astrogliosis. Acta Neuropathol 2013; 125: 609-620.
141. Lu D-Y, Leung Y-M, Cheung C-W, et al. Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem Pharmacol 2010; 80: 1201-1209.
142. Wan G, Too H-P A specific isoform of glial cell line-derived neurotrophic factor family receptor alpha 1 regulates RhoA expression and glioma cell migration. J Neurochem 2010; 115: 759-770.
143. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39-48.
144. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442-444.
145. Bergmann CE, Hoefer IE, Meder B, et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol 2006; 80: 59-65.
146. Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol 2013; 34: 81-89.
147. Wei J, Barr J, Kong L-Y, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010; 9: 67-78.
148. Hamilton JA. CSF-1 signal transduction. J Leukoc Biol 1997; 62: 145-155.
149. Yu W, Chen J, Xiong Y, et al. CSF-1 receptor structure/function in MacCsf1r - /.- macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol 2008; 84: 852-863.
150. Alterman RL, Stanley ER. Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol 1994; 21: 177-188.
151. Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012; 18: 519-527.
152. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-1272.
153. Metcalf D. The colony-stimulating factors and cancer. Cancer Immunol Res 2013; 1: 351-356.
154. Gasson JC, Kaufman SE, Weisbart RH, et al. High-Affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci USA 1986; 83: 669-673.
155. Hayashida K, Kitamura T, Gorman DM, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-Affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990; 87: 9655-9659.
156. Hercus TR, Thomas D, Guthridge MA, et al. The granulocytemacrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 2009; 114: 1289-1298.
157. Fleetwood AJ, Cook AD, Hamilton J. Functions of granulocytemacrophage colony-stimulating factor. Crit Rev Immunol 2005; 25: 405-428.
158. Frei K, Nohava K, Malipiero UV, et al. Production of macrophage colony-stimulating factor by astrocytes and brain macrophages. J Neuroimmunol 1992; 40: 189-195.
159. Guillaume T, Sekhavat M, Rubinstein DB, et al. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 1993; 53: 3139-3144.
160. Mueller MM, Herold-Mende CC, Riede D, et al. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. AmJPathol 1999; 155: 1557-1567.
161. Revoltella RP, Menicagli M, Campani D. Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 2012; 57: 347-359.
162. Murata J, Sawamura Y, Tada M, et al. Human glioblastoma cells produce granulocyte-macrophage colony-stimulating factor in vitro, but not in vivo, without expressing its receptor. Neurol Med Chir 1993; 33: 603-609.
163. Curran CS, Evans MD, Bertics PJ. GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol 2011; 187: 1254-1263.
164. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res 2013; 73: 6413-6423.
165. Kaminska B, Kocyk M, Kijewska M. TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol 2013; 986: 171-187.
166. Bruna A, Darken RS, Rojo F, et al. High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007; 11: 147-160.
167. Verrecchia F, Mauviel A. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 2002; 4: 143-149.
168. Leivonen S-K, Kähäri V-M. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007; 121: 2119-2124.
169. Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148: 1404-1410.
170. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989; 143: 3222-3229.
171. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000; 89: 251-258.
172. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12: 1113-1125.
173. Taniguchi Y, Ono K, Yoshida S, et al. Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J Neuroimmunol 2000; 111: 177-185.
174. Nakano Y, Kuroda E, Kito T, et al. Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase-1 expression in murine microglia by glioma-derived soluble factors. Laboratory investigation. J Neurosurg 2008; 108: 311-319.
175. Suzumura A, Sawada M, Yamamoto H, et al. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 1993; 151: 2150-2158.
176. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10: 554-567.
177. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64: 7596-7603.
178. Crane CA, Han SJ, Barry JJ, et al. TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010; 12: 7-13.
179. Kiefer R, Supler ML, Toyka KV, et al. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive glial cells. Neurosci Lett 1994; 166: 161-164.
180. Wesolowska A, Kwiatkowska A, Slomnicki L, et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion-An inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene 2007; 27: 918-930.
181. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012; 14: 958-978.
182. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118.
183. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345.
184. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-Translational phosphorylation and protein folding. J Cell Biochem 2007; 102: 912-924.
185. Saitoh Y, Kuratsu J, Takeshima H, et al. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995; 72: 55-63.
186. Sreekanthreddy P, Srinivasan H, Kumar DM, et al. Identification of potential serum biomarkers of glioblastoma: Serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1409-1422.
187. Matusan-Ilijas K, Behrem S, Jonjic N, et al. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res 2008; 14: 293-298.
188. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006; 25: 2192-2202.
189. Yan W, Qian C, Zhao P, et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 2010; 12: 765-775.
190. Anborgh PH, Mutrie JC, Tuck AB, et al. Pre- And post-Translational regulation of osteopontin in cancer. J Cell Commun Signal 2011; 5: 111-122.
191. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055-1061.
192. Yokosaki Y, Tanaka K, Higashikawa F, et al. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 2005; 24: 418-427.
193. Sharif SA, Du X, Myles T, et al. Thrombin-Activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2902-2912.
194. Laffon A, Garcia-Vicuna R, Humbria A, et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991; 88: 546-552.
195. Yokosaki Y, Matsuura N, Sasaki T, et al. The integrin alpha9beta1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-Terminal fragment of osteopontin. J Biol Chem 1999; 274: 36328-36334.
196. Ito K, Kon S, Nakayama Y, et al. The differential amino acid requirement within osteopontin in aplha4 and alpha9 integrin-mediated cell binding and migration. Matrix Biol 2009; 28: 11-19.
197. Nishimichi N, Higashikawa F, Kinoh HH, et al. Polymeric osteopontin employs integrin alpha9beta1 as a receptor and attracts neutrophils by presenting a de Novo binding site. J Biol Chem 2009; 284: 14769-14776.
198. Diao H, Iwabuchi K, Li L, et al. Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci USA 2008; 105: 15884-15889.
199. Fong YC, Liu SC, Huang CY, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009; 64: 263-270.
200. Atai NA, Bansal M, Lo C, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 2011; 132: 39-48.
201. Yamaguchi Y, Shao Z, Sharif S, et al. Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem 2013; 288: 3097-3111.
202. Giachelli CM, Lombardi D, Johnson RJ, et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-358.
203. Pietras A, Katz AM, Ekström EJ, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 2014; 14: 357-369.
204. Lamour V, Henry A, Kroonen J, et al. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Int J Cancer 2015; 137: 1047-1057.
205. Ellert-Miklaszewska A, Wisniewski P, Kijewska M, et al. Tumourprocessed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene 2016; 35: 6366-6377.
206. Takeshita S, Kikuno R, Tezuka K, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993; 294: 271-278.
207. Rani S, Barbe MF, Barr AE, et al. Induction of periostin-like factor and periostin in forearm muscle, tendon, and nerve in an animal model of work-related musculoskeletal disorder. J Histochem Cytochem 2009; 57: 1061-1073.
208. Morra L, Rechsteiner M, Casagrande S, et al. Relevance of periostin splice variants in renal cell carcinoma. Am J Pathol 2011; 179: 1513-1521.
209. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5: 329-339.
210. Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85-89.
211. Michaylira CZ, Wong GS, Miller CG, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 2010; 70: 5281-5292.
212. Baril P, Gangeswaran R, Mahon PC, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxiainduced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007; 26: 2082-2094.
213. Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-Associated macrophages and promotes malignant growth. Nat Cell Biol 2015; 17: 170-182.
214. Mikheev AM, Mikheeva SA, Trister AD, et al. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy. Neuro Oncol 2015; 17: 372-382.
215. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-412.
216. Yamada S, Bu XY, Khankaldyyan V, et al. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006; 59: 1304-1312.
217. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-1108.
218. Weller M, Nabors LB, Gorlia T, et al. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget 2016; 7: 15018-15032.
219. Markovic DS, Vinnakota K, Chirasani S, et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci USA 2009; 106: 12530-12535.
220. Arslan F, Bosserhoff A-K, Nickl-Jockschat T, et al. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96: 1560-1568.
221. Onken J, Moeckel S, Leukel P, et al. Versican isoform V1 regulates proliferation and migration in high-grade gliomas. J Neurooncol 2014; 120: 73-83.
222. Vinnakota K, Hu F, Ku MC, et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol 2013; 15: 1457-1468.
223. Wu YJ, La Pierre DP, Wu J, et al. The interaction of versican with its binding partners. Cell Res 2005; 15: 483-494.
224. Kim S, Takahashi H, Lin W-W, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-106.
225. Hu F, Dzaye ODA, Hahn A, et al. Glioma-derived versican promotes tumor expansion via glioma-Associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol 2015; 17: 200-210.
226. Clark MJ, Homer N, O'Connor BD, et al. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 2010; 6.
227. Badie B, Goh CS, Klaver J, et al. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther 1999; 6: 155-162.
228. Lazovic J, Soto H, Piccioni D, et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 2012; 14: 1465-1472.
229. Jung TY, Choi YD, Kim YH, et al. Immunological characterization of glioblastoma cells for immunotherapy. Anticancer Res 2013; 33: 2525-2534.
230. Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation. Oncogene 1998; 17: 1567-1575.
231. Zhang R, Banik NL, Ray SK. Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis. Brain Res 2008; 1239: 216-225.
232. Kumar PS, Shiras A, Das G, et al. Differential expression and role of p21cip/waf1 and p27kip1 in TNF-Alpha-induced inhibition of proliferation in human glioma cells. Mol Cancer 2007; 6: 42.
233. Szatmári T, Lumniczky K, Désaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97: 546-553.
234. Zagzag D, Salnikow K, Chiriboga L, et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005; 85: 328-341.
235. Merkel CA, da Silva Soares RB, de Carvalho ACV, et al. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer 2010; 10: 316.
236. Kyrkanides S, Miller AW, Miller JH, et al. Peripheral blood mononuclear cell infiltration and neuroinflammation in the HexB-/- mouse model of neurodegeneration. J Neuroimmunol 2008; 203: 50-57.
237. Kronlage M, Song J, Sorokin L, et al. Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis. Sci Signal 2010; 3: ra55-ra55.
238. Webster CM, Hokari M, McManus A, et al. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS One 2013; 8: e70927.
239. Ford JW and McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009; 21: 38-46.
240. Neumann H, Takahashi K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 2007; 184: 92-99.
241. Bédard A, Tremblay P, Chernomoretz A, et al. Identification of genes preferentially expressed by microglia and upregulated during cuprizone-induced inflammation. Glia 2007; 55: 777-789.
242. Fuhrmann M, Bittner T, Jung CKE, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010; 13: 411-413.
243. Held-Feindt J, Hattermann K, Muerkoster SS, et al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res 2010; 316: 1553-1566.
244. Kopatz J, Beutner C, Welle K, et al. Siglec-h on activated microglia for recognition and engulfment of glioma cells. Glia 2013; 61: 1122-1133.
245. Walters MJ, Ebsworth K, Berahovich RD, et al. Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer 2014; 110: 1179-1188.
246. Han JH, Lee S, Park YS, et al. IFITM6 expression is increased in macrophages of tumor-bearing mice. Oncol Rep 2011; 25: 531-536.
247. Wang J, Shiratori I, Uehori J, et al. Neutrophil infiltration during inflammation is regulated by PILRα via modulation of integrin activation. Nat Immunol 2013; 14: 34-40.
248. Yee NK, Hamerman JA. β(2) integrins inhibit TLR responses by regulating NF-'B pathway and p38 MAPK activation. Eur J Immunol 2013; 43: 779-792.